Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Operating expenses:
Research and development	$ 7,015,299	$ 3,462,991
General and administrative	2,328,500	2,066,152
Loss from operations	(9,343,799)	(5,529,143)
Interest income	520,139	958,517
Other income (expense)	143,088	(6,635)
Net loss	$ (8,680,572)	$ (4,577,261)
Net income (loss) per share - basic (in dollars per share)	$ (0.09)	$ (0.05)
Net income (loss) per share - diluted (in dollars per share)	$ (0.09)	$ (0.05)
Weighted average common shares outstanding - basic (in shares)	95,183,718	95,186,935
Weighted average common shares outstanding - diluted (in shares)	95,183,718	95,186,935